PRMT1 and acute myeloid leukemia: As proof of principle, we provide the long-sought-after in vivo preclinical data showing that inhibition of Prmt1 activity by shRNA or chemical inhibitor approaches can significantly suppress oncogenic transformation mediated by various AML fusions, and extend the latency of established disease in the transplanted animals.